Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.

Employees

47,455

Sector

Pharmaceuticals

Calendar

30/03 - Final dividend

More about the company

Quotes

Date	Price	Change	Volume
13/26/13	5,614.00 ¥	+0.09%	51,77,800
12/26/12	5,609.00 ¥	+0.50%	45,01,600
10/26/10	5,581.00 ¥	+1.40%	50,33,900
09/26/09	5,504.00 ¥	-0.24%	57,55,300
06/26/06	5,517.00 ¥	-1.34%	48,68,100

Delayed Quote Japan Exchange

More quotes

Income Statement and Estimates

More financial data

Analysis / Opinion

Takeda CEO Weber on Drug Pipeline, Geopolitical Risks

January 14, 2025 at 02:01 am IST

More analyses

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

5,614.00JPY

Average target price

5,383.07JPY

Spread / Average Target

-4.11%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Japan Exchange Other stock markets 12:00:00 13/02/2026 pm IST			5-day change	1st Jan Change
5,614.00 ^JPY	+0.09%		+1.76%	+16.11%

10/02	Takeda Pharmaceutical Says NDA for Oveporexton Gets FDA Acceptance	MT
10/02	U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda Pharmaceutical Company Limited's Oveporexton (TAK-861) as A Potential First-In-Class Therapy for Narcolepsy Type 1	CI

Capitalization	8,86800Cr 5.8TCr 4.89TCr 4.46TCr 4.26TCr 7.9TCr 5,25400Cr 8.21TCr 52TCr 21TCr 2,53700Cr 22TCr 21TCr	P/E ratio 2026 *	51.6x	P/E ratio 2027 *	29.8x
Enterprise value	12,93800Cr 8.46TCr 7.13TCr 6.5TCr 6.21TCr 12TCr 7,66600Cr 12TCr 76TCr 30TCr 3,70200Cr 32TCr 31TCr	EV / Sales 2026 *	2.86x	EV / Sales 2027 *	2.74x
Free-Float	99.61%	Yield 2026 *	3.56%	Yield 2027 *	3.62%

10/02	Takeda Pharmaceutical Says NDA for Oveporexton Gets FDA Acceptance	MT
10/02	U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda Pharmaceutical Company Limited's Oveporexton (TAK-861) as A Potential First-In-Class Therapy for Narcolepsy Type 1	CI
10/02	Takeda Pharmaceutical Co Ltd - U.S. FDA accepts NDA and grants Priority Review for Takeda's Oveporexton (TAK-861) as a potential first-in-class therapy for narcolepsy type 1	RE
10/02	Takeda Pharmaceutical Enters Technology, Discovery Collaboration Deal With Iambic	MT
09/02	Iambic announces collaboration with Takeda to advance AI-driven design of small molecules	RE
09/02	Iambic Announces Collaboration with Takeda to Advance AI-Driven Design of Small Molecules	CI
06/02	Japanese drugmakers slump after Trump unveils discount drug website	RE
05/02	Alvotech Reports Positive Results of Pharmacokinetic Study for Entyvio Biosimilar	MT
04/02	Takeda, Kyoto University to End Decade-Long iPS Research Tie-Up	MT
30/01	Jefferies Adjusts Takeda Pharmaceutical's Price Target to 5,700 Yen From 5,100 Yen, Keeps at Buy	MT
29/01	Takeda Pharmaceutical Company Limited, Q3 2026 Earnings Call, Jan 29, 2026
29/01	Takeda Pharmaceutical Company Limited Reports Earnings Results for the Nine Months Ended December 31, 2025	CI
29/01	Takeda Pharmaceutical Company Limited Provides Dividend Guidance for the Fiscal Year Ending March 31, 2026	CI

30/01	Jefferies Adjusts Takeda Pharmaceutical's Price Target to 5,700 Yen From 5,100 Yen, Keeps at Buy	MT
11/11	Neurocrine Biosciences' Depressive Disorder Drug Fails to Meet Primary Goal in Phase 2 Study	MT
26/25/26	Alkermes' Stock Dip on Narcolepsy Data Seen as Buying Opportunity, RBC Says	MT
21/25/21	Veeva Systems Q2 Results Likely In-Line to Better, Maintain H2 Outlook, Truist Says	MT
09/25/09	Jefferies Adjusts Takeda Pharmaceutical's Price Target to 5,100 Yen From 5,500 Yen, Keeps at Buy	MT

Takeda Pharmaceutical Company Limited Share Price

Equities

4502

JP3463000004

Pharmaceuticals

Valuation: Takeda Pharmaceutical Company Limited

Chart: Takeda Pharmaceutical Company Limited

Latest news: Takeda Pharmaceutical Company Limited

Last Transcript: Takeda Pharmaceutical Company Limited

Analysts' recommendations: Takeda Pharmaceutical Company Limited

Press Releases: Takeda Pharmaceutical Company Limited

News in other languages: Takeda Pharmaceutical Company Limited

Quotes and Performance

Course Extremes

Managers and Directors: Takeda Pharmaceutical Company Limited

ETFs: Takeda Pharmaceutical Company Limited

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysis / Opinion

Analysts' Consensus

Quarterly revenue - Rate of surprise

11/02	U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda's Oveporexton as a Potential First-in-Class Therapy for Narcolepsy Type 1	AQ
10/02	U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1	BU
10/02	Takeda Pharmaceutical : U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1	PU
30/01	Takeda Reports Third-Quarter FY2025 Results, Updates Full Year Outlook to Reflect VYVANSE Generics Impact, OPEX Discipline and FX Tailwind, Progressing Toward Three Transformative Launches Ahead	AQ
29/01	Takeda Pharmaceutical : Earnings Report（Kessan Tanshin）Earnings Report（Kessan Tanshin）Download Earnings Report（Kessan Tanshin） (qr2025 q3 er en)	PU

29/01	Bourse : SAP, STMicro, Sanofi, Roche, Microsoft, IBM… avalanche de publications !
29/01	Bessent, Trump, deux salles, deux ambiances
26/11	Japanische Takeda erweitert Produktionsstandort in Neuenburg
26/11	Le géant nippon Takeda étend son site de production neuchâtelois
01/25/01	USA-Les valeurs à suivre à Wall Street (actualisé)

1 day	+0.09%
1 week	+1.76%
Current month	+7.10%
1 month	+11.83%
3 months	+28.17%
6 months	+28.85%
Current year	+16.11%

1 week	5,491	5,650
1 month	4,956	5,650
Current year	4,863	5,650
1 year	3,916	5,650
3 years	3,852	5,650
5 years	2,993	5,650
10 years	2,894.5	6,693

Manager	Title	Age	Since
Christophe Weber CEO	Chief Executive Officer	59	01/04/2015
Milano Furuta DFI	Director of Finance/CFO	-	01/04/2024
Mwana Lugogo CMP	Compliance Officer	56	01/01/2012

Director	Title	Age	Since
Christophe Weber BRD	Director/Board Member	59	01/06/2014
Andrew Plump BRD	Director/Board Member	60	01/06/2015
Yoshiaki Fujimori BRD	Director/Board Member	73	01/06/2016

Name	Varia. Jan 1.	Weight	AuM
NOMURA NEXT FUNDS TOPIX-17 PHARMACEUTICAL ETF - JPY	+10.06%	24.44%	29 M€
DAIWA ETF TOPIX HIGH DIVIDEND YIELD 40 INDEX ETF - JPY	+17.05%	5%	476 M€
NOMURA NEXT FUNDS NIKKEI 225 HIGH DIVIDEND YIELD STOCK 50 INDEX ETF - JPY	+14.87%	3.8%	2,604 M€
NEXT FUNDS TOPIX CORE 30 ETF - JPY	+11.94%	3.26%	96 M€

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
TAKEDA PHARMACEUTICAL COMPANY LIMITED	+0.09%	+1.76%	+34.24%	+34.43%	5.8TCr
ELI LILLY AND COMPANY	+0.33%	-1.72%	+23.18%	+199.23%	93TCr
JOHNSON & JOHNSON	-0.45%	+1.44%	+55.91%	+50.24%	59TCr
ABBVIE INC.	+1.76%	+3.61%	+20.03%	+51.71%	41TCr
ROCHE HOLDING AG	+0.08%	+1.01%	+20.89%	+28.94%	37TCr
ASTRAZENECA PLC	+1.42%	+7.19%	+26.36%	+32.36%	32TCr
NOVARTIS AG	+1.08%	+4.32%	+27.98%	+55.61%	31TCr
MERCK & CO., INC.	+1.82%	-0.43%	+46.26%	+11.65%	30TCr
NOVO NORDISK A/S	+1.32%	+5.11%	-45.12%	-37.51%	22TCr
AMGEN INC.	+1.52%	-3.94%	+26.80%	+53.17%	20TCr
Average	+0.90%	+1.98%	+23.65%	+47.98%	37.07TCr
Weighted average by Cap.	+0.74%	+1.58%	+26.66%	+76.09%

	2026 *	2027 *
Net sales	4,51700Cr 2.96TCr 2.49TCr 2.27TCr 2.17TCr 4.02TCr 2,67600Cr 4.18TCr 26TCr 10TCr 1,29200Cr 11TCr 11TCr	4,56100Cr 2.98TCr 2.51TCr 2.29TCr 2.19TCr 4.06TCr 2,70200Cr 4.22TCr 27TCr 11TCr 1,30500Cr 11TCr 11TCr
Net income	17TCr 112.04Cr 94Cr 86Cr 82Cr 152.6Cr 10TCr 158.55Cr 1TCr 397.59Cr 4.9TCr 420.18Cr 411.54Cr	29TCr 191.71Cr 161.54Cr 147.34Cr 140.66Cr 261.11Cr 17TCr 271.29Cr 1.71TCr 680.31Cr 8.39TCr 718.96Cr 704.18Cr
Net Debt	4,07000Cr 2.66TCr 2.24TCr 2.05TCr 1.95TCr 3.63TCr 2,41200Cr 3.77TCr 24TCr 9.45TCr 1,16500Cr 9.98TCr 9.78TCr	3,63200Cr 2.38TCr 2TCr 1.83TCr 1.74TCr 3.24TCr 2,15200Cr 3.36TCr 21TCr 8.43TCr 1,03900Cr 8.91TCr 8.73TCr